TIG Advisors LLC’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

TIG Advisors LLC’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-237,400	Closed	-$5.48M	–	468
2020 Q4	$5.48M	Buy	+237,400	New	+$3.01M	0.27%	56

TIG Advisors LLC's PRVL Position: Q1 2021 in Review

TIG Advisors LLC sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 709,282 shares — an estimated $16.4M sold.

TIG Advisors LLC first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $16.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

TIG Advisors LLC reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
TIG Advisors LLC sold 709,282 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $16.4M.
TIG Advisors LLC first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
TIG Advisors LLC's Prevail Therapeutics Inc. Common Stock position peaked at $16.4M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on TIG Advisors LLC's 13F filing for Q1 2021, filed 18 May 2021.